The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain by Skerratt, Sarah E. et al.
Kent Academic Repository
Full text document (pdf)
Copyright & reuse
Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all
content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions 
for further reuse of content should be sought from the publisher, author or other copyright holder. 
Versions of research
The version in the Kent Academic Repository may differ from the final published version. 
Users are advised to check http://kar.kent.ac.uk for the status of the paper. Users should always cite the 
published version of record.
Enquiries
For any further enquiries regarding the licence status of this document, please contact: 
researchsupport@kent.ac.uk
If you believe this document infringes copyright then please contact the KAR admin team with the take-down 
information provided at http://kar.kent.ac.uk/contact.html
Citation for published version
Skerratt, Sarah E. and Andrews, Mark and Bagal, Sharan K. and Bilsland, James and Brown,
David and Bungay, Peter J. and Cole, Susan and Gibson, Karl R and Jones, Russell and Morao,
Inaki and Nedderman, Angus and Omoto, Kiyoyuki and Robinson, Colin and Ryckmans, Thomas
and Skinner, Kimberly and Stupple, Paul and Waldron, Gareth  (2016) The Discovery of a Potent,
DOI
http://doi.org/10.1021/acs.jmedchem.6b00850




The Discovery of a Potent, Selective, and Peripherally Restricted Pan-
Trk Inhibitor (PF-06273340) for the Treatment of Pain
Sarah E. Skerratt,*, Mark Andrews, Sharan K. Bagal, James Bilsland, David Brown, Peter J. Bungay,
Susan Cole, Karl R Gibson, Russell Jones, Inaki Morao, Angus Nedderman, Kiyoyuki Omoto,
Colin Robinson, Thomas Ryckmans, Kimberly Skinner, Paul Stupple, and Gareth Waldron
Pﬁzer Global Research & Development, The Portway Building, Granta Park, Great Abington, Cambridge, CB21 6GS, U.K.
Pﬁzer Global Research & Development, Ramsgate Road, Sandwich CT13 9NJ, U.K.
*S Supporting Information
ABSTRACT: The neurotrophin family of growth factors, comprised of nerve growth factor (NGF), brain derived neurotrophic
factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4), is implicated in the physiology of chronic pain. Given the
clinical eﬃcacy of anti-NGF monoclonal antibody (mAb) therapies, there is signiﬁcant interest in the development of small
molecule modulators of neurotrophin activity. Neurotrophins signal through the tropomyosin related kinase (Trk) family of
tyrosine kinase receptors, hence Trk kinase inhibition represents a potentially “druggable” point of intervention. To deliver the
safety proﬁle required for chronic, nonlife threatening pain indications, highly kinase-selective Trk inhibitors with minimal brain
availability are sought. Herein we describe how the use of SBDD, 2D QSAR models, and matched molecular pair data in
compound design enabled the delivery of the highly potent, kinase-selective, and peripherally restricted clinical candidate PF-
06273340.
■ INTRODUCTION
The neurotrophin family of growth factors, composed of nerve
growth factor (NGF), brain derived neurotrophic factor
(BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4),
is implicated in the physiology of chronic pain. Preclinical and
clinical studies have identiﬁed a crucial role for NGF in the
pathogenesis of inﬂammatory pain,1 with neutralizing antibod-
ies demonstrating eﬃcacy in preclinical pain models and in
clinical trials for osteoarthritis, chronic lower back pain, and
interstitial cystitis.2−5 BDNF has also been implicated in the
pathogenesis of chronic pain and has been shown to be
upregulated in clinical pain states.6 Given the role of NGF and
BDNF in modulating pain and the clinical eﬃcacy of anti-NGF
monoclonal antibody (mAb) therapies, there is signiﬁcant
interest in the development of small molecule oral therapeutics
to complement existing treatment options.
Neurotrophins signal through the tropomyosin related kinase
(Trk) family of tyrosine kinase receptors, whereby NGF signals
preferentially through TrkA, BDNF and NT-4 through TrkB,
and NT-3 through TrkC. All neurotrophins interact with equal
aﬃnity at the p75 receptor, a member of the TNFR
superfamily. An alternative point of intervention, high in the
neurotrophin signaling cascade and amenable to small molecule
therapy, could therefore be the inhibition of intracellular Trk
kinases (Figure 1).7,8
A key concern in the development of Trk kinase inhibitors
for the treatment of chronic pain is the potential risk of central
nervous system (CNS) adverse events. TrkB is expressed
throughout the CNS with the BDNF/TrkB axis involved in
excitatory signaling, long-term potentiation, and feeding
behavior.9−12 TrkA is highly expressed in the cholinergic
neurons of the basal forebrain, with TrkA gene ablation leading
to dysfunction in cholinergic circuitry in preclinical spe-
cies.13−15 In addition, clinical CNS side eﬀects have been
noted with 1-(5-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d]-
pyrimidine-5-carbonyl)-2-methoxyphenyl)-3-(2,4-dichloro-
phenyl) urea (CE-245677), an oral pan-Trk/Tie2 kinase
inhibitor identiﬁed by Pﬁzer previously in development for
the treatment of certain cancers.16 Phase I multiple dose trials
were stopped due to the development of signiﬁcant CNS
adverse events which included cognitive deﬁcits, personality
changes, and sleep disturbances. These eﬀects fully resolved
upon cessation of dosing. Preclinical studies with this
compound have shown it to be eﬃcacious in multiple pain
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models. However, at doses associated with signiﬁcant (>50%)
CNS Trk receptor occupancy, changes in cortical electro-
encephalography (EEG), cognitive function, body weight, and
hypothalamic mRNA were observed.17 These ﬁndings were
recapitulated with pan-Trk inhibitors devoid of Tie-2 kinase
activity (data not shown). These data conﬁrm the potential of
small molecule Trk kinase inhibitors as pain therapeutics but
highlight the risk of on-target adverse events resulting from
pharmacologically relevant exposure in the CNS.
Given the therapeutic eﬃcacy of brain restricted anti-NGF
mAb therapies and the known safety risks associated with CNS
Trk receptor occupancy, a rational approach to delivering a
well-tolerated Trk kinase therapeutic is to restrict compounds
to the peripheral compartment. It is known from projects
within Pﬁzer and the wider pharmaceutical community that it is
possible to deliver small molecules that are orally bioavailable
yet peripherally restricted.18−22 The design of compounds in
physicochemical space appropriate for absorption across the
gastrointestinal (GI) epithelium (e.g., molecular weight <500,
polar surface area <140, <10 rotatable bonds)23 but that are
substrates for blood−brain barrier (BBB) eﬄux transporters
such as P-glycoprotein (P-gp) and breast cancer resistance
protein (BCRP) is an emerging strategy to deliver this type of
proﬁle. According to the free drug hypothesis, unbound
concentration determines a drug’s pharmacological eﬀect. If a
drug is a substrate for BBB eﬄux transporters, the unbound
brain concentration (Cb,u) may be less than the unbound
plasma concentration (Cp,u). An example of a compound that
exhibits signiﬁcant peripheral restriction (via targeting BBB
eﬄux transporters P-gp and BCRP) while retaining good oral
bioavailability, cell penetration, and pharmacological activity is
the tyrosine kinase inhibitor imatinib.24 Imatinib was not
speciﬁcally designed to be peripherally restricted, yet
discoveries such as this engender knowledge of how to
prospectively design orally bioavailable, peripherally restricted
molecules in a rational manner.
Targeting transporters in order to achieve peripheral
restriction can introduce risk factors.20 For example, the apical
membrane of intestinal epithelial cells contains the same eﬄux
transporter proteins P-gp and BCRP found at the BBB. Drugs
that are eﬄux substrates could therefore be restricted in their
passage across the intestinal epithelium, resulting in poor
absorption from the gut lumen (Figure 2). Set against this risk
(at commonly prescribed oral drug doses of adequately soluble
compounds (10−500 mg)), the intraluminal compound
concentration is likely to be in the range of hundreds of
micromolar providing a high concentration gradient which, for
a compound with suﬃcient permeability, will mean a high
driving force for ﬂux across the epithelium. In addition, such
gut luminal concentrations are likely to be high enough to
saturate eﬄux transporters, given that substrates of P-gp
typically possess Km values in the range 1−100 μM. These
considerations suggest that in most cases, the risk of poor
absorption and nonlinear pharmacokinetics of orally delivered
eﬄux substrates will be low.25
An additional requirement for a small molecule Trk kinase
inhibitor, suitable for chronic administration in a nonlife
threatening indication, is exquisite kinase selectivity. Kinases
modulate numerous physiological functions and hence
inhibiting oﬀ-target kinases can lead to unwanted safety side
eﬀects.26,27 The majority of kinase inhibitors bind to the highly
conserved ATP binding site (type I inhibitors) and hence can
be nonselective. A strategy that has emerged to design kinase
inhibitors with enhanced kinase selectivity is to target protein−
ligand interactions in less conserved areas of the ligand binding
Figure 1. Neurotrophins NGF, BDNF, NT-3, NT-4/5, and their receptors TrkA, TrkB, and TrkC.
Figure 2. Schematic illustration of orally administered drug absorption
across the intestinal epithelium and distribution across the brain
vascular endothelium. Cp,u = unbound plasma concentration, Cb,u =
unbound brain concentration, and Ci,u = unbound intracellular
concentration.
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domain outside of the ATP binding pocket.28−31 Imatinib, a
type II kinase inhibitor, is a well-established example of this
whereby it binds to the inactive form of the Abl protein in
which the N-terminal region of the activation loop adopts a
Asp-Phe-Gly-out (DFG-out) conformation (see Supporting
Information, page S2). Because the deep pocket region
accessible in a DFG-out conformation has a relatively low
sequence conservation compared to other kinases, imatinib has
been shown to be a relatively selective kinase inhibitor.30−32
Indeed, when Karaman et al. generated KINOMEscan
selectivity scores for a selection of marketed kinase inhibitors,
they demonstrated the potential for type II inhibitors such as
imatinib, sorafenib, and lapatinib to display higher selectivity
than type I inhibitors such as sunitinib and dasatinib, especially
when only higher aﬃnity oﬀ-target interactions were
considered.33,34 While kinase inhibitors adopting a DFG-out
conformation are certainly not guaranteed to be highly kinome-
selective,35,36 this binding mode oﬀers the opportunity to access
an allosteric binding pocket adjacent to the ATP-binding site
and target unique inactive conformations.37
Herein we describe the discovery of a highly potent, kinase-
selective, peripherally restricted, eﬃcacious, and well-tolerated
series of “DFG-out” pan-Trk inhibitors. The use of SBDD, 2D
QSAR models and matched molecular pair data in prospective
Figure 3. Crystal structure of 1 (green) bound to TrkA (pink). The hinge region of the TrkA ATP site is highlighted in blue. The “DFG” triad of the
activation loop of TrkA is highlighted in orange. Key protein−ligand binding interactions are highlighted.
Table 1. Structure and Properties of Compounds 1−4 (ND = Not Determined)
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design enabled rapid optimization of the lead chemical series
and delivery of clinical candidate 14 (PF-06273340).38
■ RESULTS AND DISCUSSION
Hit Identiﬁcation and Characterization. A high
throughput screen of the Pﬁzer compound collection was
conducted using TrkA and TrkB cell-based assays.38 Of the
numerous chemical series of pan-Trk inhibitors identiﬁed,
prioritization for lead optimization follow-up was based on
criteria that included LipE,23 predicted levels of kinase
promiscuity,39 and predicted ATP-site binding mode. Chemical
series with an anticipated DFG-out binding mode were
prioritized, as it is known that kinase inhibitors that bind to
less conserved areas of the ATP binding site can be more
selective within the kinome. Indeed, when a systematic analysis
of kinase structural and kinase panel screening data was
undertaken within Pﬁzer, it was shown that ligands that contact
ATP-site residues approaching the “back pocket” of the ATP
site have a higher chance of being kinase-selective.40 Assess-
ment of compound binding mode was made via docking into a
TrkA homology model built on a set of in-house cFMS crystal
structures.
Several chemical series were identiﬁed that demonstrated
moderate to good LipE proﬁles were calculated to have high
levels of kinase selectivity and predicted to adopt a DFG-out
binding mode. One of the series selected for lead optimization
was the pyrrolopyrimidine urea series.41 An example from this
series, 1,41 is highlighted in Figure 3 and Table 1. Compound 1
is a potent inhibitor of TrkA, TrkB, and TrkC in recombinant
cellular assays.38 Trk isoform selectivity is not anticipated
within this series due to the highly homologous nature of the
TrkA, B, and C DFG-out ligand binding sites.42 The overall
kinase selectivity proﬁle of 1 is encouraging (Figure 12), with
only ﬁve kinases (including TrkA) in a panel of 39 biochemical
kinase assays from Invitrogen showing >50% inhibition (%I) at
a compound concentration of 1 μM. The kinase selectivity
proﬁle of 1 is represented as a Gini coeﬃcient which describes
the selectivity of a compound by a single number between 0
and 1. Nonselective inhibitors are characterized by Gini values
close to zero (e.g., Staurosporine, Gini 0.15), whereas
compounds with complete selectivity exhibit Gini values of
1.43 Compound 1 has a Gini value of 0.59, indicative of its
moderate kinase selectivity, representing an encouraging start-
point for further optimization.
Compound 1 was predicted to adopt a DFG-out binding
pose in the TrkA homology model, which was subsequently
conﬁrmed by X-ray crystallography studies. Figure 3 shows the
crystal structure of 1 bound to the TrkA kinase and highlights
the key protein−ligand interactions. The 4-amino pyrrolopyr-
imidine motif of 1 makes a two-point hydrogen bonding
interaction with backbone polar atoms of hinge residues
Glu590 and Met592, while the central pyridyl group of 1 makes
a π-stacking interaction with the gatekeeper (Phe589) and
Phe669 of the DFG triad. The carbonyl oxygen of the urea
group of 1 makes a hydrogen bond interaction with the
backbone N−H of Asp 668 from the DFG triad. The N−H
groups of the urea group of 1 make hydrogen bond interactions
with a conserved water molecule, which further interacts with
catalytic lysine (Lys544) and Glu560 from the α-C helix. The
lipophilic “DFG-out” back pocket accommodates the 1,3-
diﬂuorophenyl group.
Although potent, the lipophilic eﬃciency of 1 is moderate
(LipE 3.4) due to the highly lipophilic nature of the molecule
(log D 4.6). The metabolic stability of 1 in human liver
microsomes (HLM) and human hepatocytes (hHep) is
encouraging and may be high enough to deliver low metabolic
clearance (CL) in humans. Also encouraging is the lack of
blockade of the human ether-a-go-go related gene (hERG)
encoded potassium channel, as demonstrated by the lack of
signal in the dofetilide binding assay.44,45 Compound 1 is a
weak substrate for the eﬄux transporter P-gp (eﬄux ratio (ER)
in the MDCK-MDR1 assay = 2.1) is poorly soluble (<0.3 μM
at pH 6.5) and has low passive permeability (RRCK A to B
apparent permeability (Papp) = 0.6 × 10
−6 cms−1), such that
limitations on oral bioavailability may be expected in the
absence of formulation enhancement.
Hit to Lead: Improving Solubility. After identiﬁcation of
the pyrrolopyrimidine series (e.g., 1), an initial round of
synthesis aimed at improving the aqueous solubility proﬁle was
undertaken. It is known that urea-containing compounds often
have a poor solubility proﬁle, and a commonly used strategy to
try and improve solubility is to replace the urea group with an
amide unit. Indeed, a matched molecular pair (MMP) analysis
of the Pﬁzer Pairwise Database46 showed that conversion of an
urea to an amide group (R1-NHCONH-R2 → R1-NHCOCH2-
R2) increased solubility (>2-fold) in 52% of cases, maintained
solubility within 2-fold in 39% of cases, and decreased solubility
(>2-fold decrease) in only 9% of cases, with a mean increase in
solubility of 137 μM (no. of pairs = 56).47 Replacing the urea
group for an amide unit in the pyrrolopyrimidine series
maintained TrkA potency and on average facilitated a > 30-fold
increase in solubility. In addition, the passive permeability of
the amide-containing analogues was superior. An example, 2
(the direct matched pair of 1), is highlighted in Table 1.
Because of the superior solubility and permeability proﬁle, all
further ligand optimization was conducted using the amide
linker group.
Hit to Lead: Improving Kinase Selectivity. While the
initial kinase selectivity proﬁle of the DFG-out pyrrolopyr-
imidine series was promising, an early design objective was to
further improve the kinase selectivity to optimize the overall
safety proﬁle. Kinase inhibitors generally form one to three
hydrogen bonds with backbone polar atoms of the kinase hinge
region that connects the N- and C-terminal lobes of the
catalytic domain, with an increasing number of hydrogen bonds
thought to negatively aﬀect overall kinase selectivity.48 Indeed,
when a systematic analysis of kinase scaﬀolds extracted from the
Pﬁzer Crystal Structure Database (CSDb) was performed and
combined with kinase biological screening data, the authors
demonstrated that more hydrogen bonding interactions at the
hinge region do not necessarily aﬀord increased potency and
moreover may have deleterious eﬀects on kinome selectivity.49
A strategy to optimize kinase selectivity could therefore be to
minimize the number of hydrogen bonding interactions at the
hinge region. Compound 3 is a representative amino
pyrrolopyrimidine from the initial round of synthesis described
above in which the urea to amide linker transformation was
investigated (Table 1). Compound 3 is a potent inhibitor of
TrkA, TrkB, and TrkC, with a moderate lipophilic eﬃciency
proﬁle (LipE 4.0). The metabolic stability of 3 in HLM and
hHep is moderate and the hERG activity modest. Compound 3
is a relatively good substrate for the eﬄux transporter P-gp
(MDCK-MDR1 ER = 6.2), is a weak substrate for the eﬄux
transporter BCRP, and has moderate passive permeability
(RRCK A to B Papp = 15.3). The aqueous solubility is 13.2 μM.
The kinase selectivity proﬁle of 3 is promising, with only 7
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kinases (including TrkA) in a panel of 39 biochemical kinase
assays from Invitrogen showing >50% inhibition at a compound
concentration of 1 μM, generating a Gini value of 0.59 (Figure
12).
To design compounds with the minimal number of hydrogen
bond contacts at the hinge region, an analysis of the crystal
structure of 3 bound to TrkA and the nonliganded apo
structure was undertaken. The crystal structure of 3 bound to
TrkA is shown in Figure 4. Compound 3 adopts a DFG-out
binding mode, with the amino pyrrolopyrimidine motif making
a two-point hydrogen bonding interaction with hinge residues
Glu590 and Met592. When 3 is superpositioned onto the TrkA
apo crystal structure, the −NH2 motif of the amino
pyrrolopyrimidine group overlays directly with a conserved
water molecule observed in the apo structure (Figure 5). It was
hoped that removal of the −NH2 motif as highlighted in Figure
5 would deliver a ligand that makes a single hydrogen bonding
interaction with the backbone N−H of hinge residue Met592,
with a water molecule replacing the −NH2 group, satisfying the
backbone carbonyl oxygen at Glu590, and with the overall
eﬀect of improving kinase selectivity.
Deleting −NH2 at the 4-position aﬀords ligands with
comparable TrkA activity and a much improved kinase
selectivity proﬁle. An example, 4,38 is highlighted in Table 1.
Compound 4 is a potent pan-Trk inhibitor with moderate LipE
and moderate turnover in HLM and hHep. Removal of the
amino group from the pyrrolopyrimidine unit does not aﬀect
the propensity of the chemotype to be a substrate for P-gp, with
4 having an ER in the MDCK-MDR1 assay of 8.2. As with
previous pyrrolopyrimidine amide analogues, the passive
permeability of 4 is moderate (RRCK Papp = 9.9) and the
aqueous solubility relatively low (17.5 μM). A signiﬁcant
diﬀerence between 4 and its amino pyrrolopyrimidine analogue
3 is in the kinase selectivity proﬁle. Whereas 3 strongly inhibits
Figure 4. Crystal structure of 3 (green) bound to TrkA (pink). The hinge region of the TrkA ATP site is highlighted in blue. The “DFG” triad of the
activation loop of TrkA is highlighted in orange. Key binding interactions are highlighted.
Figure 5. Superposition of 3 (green) onto the TrkA apo crystal structure (pink), all water molecules included. The hinge region of the TrkA ATP
apo site is highlighted in blue. The “DFG” triad of the activation loop of TrkA is highlighted in orange. The red circle highlights the −NH2 motif of 3
that overlays directly onto a conserved water molecule observed in the apo structure.
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(>50%I) seven kinases (including TrkA) in an Invitrogen panel
of 39 biochemical kinase assays (Gini score 0.59), 4 is much
more selective (Gini score of 0.82), Figure 12.
The TrkA cocrystal structure of des-amino pyrrolopyrimidine
5,38 a close-in analogue of 4 in which the p-Cl phenyl group is
replaced with a p-CN phenyl, is shown in Figure 6. Compound
5 adopts a DFG-out binding mode and in general makes similar
protein−ligand binding interactions as amino pyrrolopyrimi-
dine 3 (Figure 4). A notable diﬀerence is the interaction
network around the hinge region. The amino pyrrolopyr-
imidine motif of 3 makes a two-point hydrogen bonding
interaction with backbone polar atoms of hinge residues
Glu590 and Met592. As Figure 6 highlights, the hydrogen bond
interaction between the pyrimidyl nitrogen of 5 and the
backbone N−H of Met592 is maintained, but a conserved
water molecule replaces the −NH2 group to make a hydrogen
bond interaction that bridges the main chain carbonyl Glu590
and the ketone oxygen atom of 5.
The presence of a bridging water between the main chain
carbonyl oxygen of TrkA Glu590 (or the equivalent across
other kinases) and a polar atom of a bound ligand is a relatively
rare occurrence. The available kinase crystal structures from the
Protein Data Bank (PDB) and the Pﬁzer Crystal Structure
Database (CSDb) were searched to identify similar water-
bridging examples using Interaction Miner, an in-house tool to
search structural databases for speciﬁc interactions and
structural motifs.50 [Interaction Miner is a Pﬁzer tool to search
structural databases for speciﬁc interactions and structural
motifs. Brieﬂy, Interaction Miner identiﬁes matching inter-
actions or structural features based on user-deﬁned atom and
bond match criteria as well as geometric constraints. The
matching database structures are superposed to the query using
RMSD overlay of the matching substructure, enabling users to
visually analyze database hits in the context of the query. The
RMSD threshold is exposed as an additional ﬁltering criterion
to restrict the database hits based on their geometric similarity
to the query substructure.] This search retrieved <10 examples
from other kinases within the RMSD threshold of <1.0 Å to the
matching atoms. Hence, as replacing the direct H-bond with a
“through water” H-bond maintained Trk activity and improved
kinase selectivity, follow-up Trk analogues within pyrrolopyr-
imidine series were devoid of an −NH2 group at the 4-position.
Peripheral Restriction: Building an in Vitro to in Vivo
Correlation. The initial rounds of compound design (as
discussed in the previous section) generated a number of
potent and selective pan-Trk inhibitors that displayed a range of
ER in the MDCK-MDR1 assay, demonstrating a spectrum of
ability to act as substrates for the eﬄux transporter P-gp. To
build an understanding of the in vitro P-gp activity required to
deliver signiﬁcant peripheral restriction in vivo, brain
distribution experiments were conducted in rats. Compounds
with a P-gp ER in the range of 1−50 were administered orally
Figure 6. Crystal structure of 5 (green) bound to TrkA (pink). The hinge region of the TrkA ATP site is highlighted in blue. The “DFG” triad of the
activation loop of TrkA is highlighted in orange. Key protein−ligand binding interactions are outlined. The red circle highlights the hydrogen bond
interactions made by a conserved water molecule bridging the main chain carbonyl Glu590 and the ketone oxygen atom of des-amino
pyrrolopyrimidine 5.
Figure 7. (A) Relationship of P-gp ER in the MDCK-MDR1 assay vs rat Cb,u/Cp,u for a range of pan Trk compounds from the pyrrolopyrimidine
series. (B) Kinase receptor occupancy proﬁle of 3 and 6 in rat brain lysates determined using the ActivX biotinylated acyl phosphate ADP probe.
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at a dose of 100 mg/kg and terminal plasma and brain samples
were taken 3 h after dosing. Compound concentrations in
plasma and homogenized brain samples were quantiﬁed in
parallel with assessment of binding of compounds to plasma
and brain tissue, such that unbound concentration ratios (Cb,u/
Cp,u) could be determined.
51 The data from the brain
penetration experiments are shown in Figure 7A. Increasing
P-gp ER results in decreased brain penetration, such that
compounds with a P-gp ER > 10 are signiﬁcantly excluded from
the CNS (Cb,u/Cp,u < 0.05). In addition, the occupancies of
TrkB and TrkC receptors in brain samples were determined
using the chemical proteomic technology developed by ActivX
Biosciences. This approach utilizes biotinylated acyl phosphates
of ADP or ATP that transfer biotin to conserved lysine residues
within the ATP binding site of kinases. Binding of a test
compound reduces binding of the probes to individual kinases,
which when combined with kinase proteomic analysis allows
receptor occupancy and broad kinase selectivity in complex
tissue lysates to be determined.52,53 Figure 7B shows the kinase
receptor occupancy proﬁle of 3 and 6 in rat brain lysates
following oral administration of compound as determined using
the ActivX biotinylated acyl phosphate ADP probe. The x-axis
of Figure 7B represents the individual kinases detected in the
rat brain lysate panel using the ActivX ADP probe, and the y-
axis represents the fold change in kinase receptor occupancy
relative to vehicle-treated animals. Compound 6 (shown as a
red circle in Figure 7B) has a high P-gp ER, is signiﬁcantly
restricted from the CNS (P-gp ER = 27.0, Cb,u/Cp,u = 0.013),
and has no detectable TrkB or TrkC occupancy in brain lysates.
Compound 3 (shown as a blue circle in Figure 7B) has a lower
P-gp ER which translates into higher brain availability (P-gp ER
= 6.2, Cb,u/Cp,u = 0.22). Compound 3 causes marked blockade
of binding of the chemical proteomic probe to TrkB and TrkC
within the CNS (TrkA not detected due to low expression) but
does not display signiﬁcant occupancy of any of the other
kinases in the brain lysate panel, demonstrating the high
selectivity of this ligand for TrkB and TrkC over other kinases.
Peripheral Restriction: Use of 2D QSAR Models to
Guide Design. As highlighted by the rat brain availability data
in Figure 7A,B, a compound with a high P-gp ER should be
signiﬁcantly restricted from the CNS. To guide the prospective
design of compounds with a high P-gp ER on the Trk project, a
2D QSAR regression model built on the Pﬁzer P-gp data set
was utilized.54 The model predicts a P-gp ER value for
proposed compounds, along with a conﬁdence value that
incorporates both the chemical similarity and activity landscape
of a test compound’s neighborhood, calibrating the value to a
probability that the prediction will be within 2-fold of the actual
experimental result. To assess the performance of the QSAR
model and conﬁdence metric, prospective predictions of P-gp
ER over time can be evaluated by comparing the model
predictions made prior to testing of the compound vs the actual
experimental P-gp data generated once tested. The result of this
analysis is shown in Figure 8. The y-axis of the trellised pie
chart in Figure 8 shows the binned P-gp ER predictions (low
predicted eﬄux, P-gp ER < 5; high predicted eﬄux, P-gp ER >
5), and the x-axis shows the conﬁdence values (0.0 to 1.0) of
the P-gp ER model predictions. A cutoﬀ of P-gp ER > 5 (cf. the
stricter cutoﬀ of P-gp ER > 10) was chosen so as not to omit
potentially interesting molecules from consideration given that
the model does not have perfect predictivity. The pies are
colored by real experimental P-gp ER data (cerise, P-gp ER < 5;
blue, P-gp ER > 5). As highlighted in Figure 8, as the
conﬁdence in the model prediction increases, the probability of
achieving the predicted P-gp ER outcome increases. In the case
of pan-Trk, the design strategy was to prioritize compounds
predicted to have high eﬄux (with high model conﬁdence) for
synthesis, disregard compounds predicted to have low eﬄux
(with high model conﬁdence), and more sparingly synthesize
compounds in the space for which the P-gp ER QSAR model
conﬁdence was not high. Utilizing TrkA cocrystal structure
information alongside the 2D QSAR P-gp ER models to
prioritize design ideas enabled an eﬃcient triage process in
which 69% of compounds in the hit to lead phase met TrkA
potency (<100 nM) and P-gp ER (ER > 5) criteria.
Lead Optimization. In addition to utilizing 2D P-gp QSAR
model data (vide supra) to guide design of compounds with a
high P-gp ER, design eﬀorts in the lead optimization phase
focused on increasing compound metabolic stability and
lipophilic eﬃciency. To increase metabolic stability, in vitro
metabolite identiﬁcation (MetID) data were used to identify
metabolic “soft spots”. Metabolite proﬁling over a range of
pyrrolopyrimidine analogues in human liver S9 fractions (in the
absence of the CYP cofactor NADP) identiﬁed aldehyde
oxidase (AO) as a likely source of metabolic oxidation. The
metabolic liabilities of representative des-amino pyrrolopyr-
imidines and amino pyrrolopyrimidines 5 (HLM < 9.8 μL/
min/mg protein, hHep 13.0 μL/min/106 cells) and 6 (HLM
Figure 8. Binned 2D QSAR P-gp ER prediction data vs binned conﬁdence in 2D QSAR P-gp ER prediction. Pies are colored by real experimental P-
gp ER data (cerise, P-gp ER < 5; blue, P-gp ER > 5).
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21.6 μL/min/mg protein, hHep 6.6 μL/min/106 cells) are
highlighted in Figure 9 (full HPLC-UV chromatograms are
available in Supporting Information, pages S3 and S4). Amino
pyrrolopyrimidine 6 has a small amount of oxidation on the
amino pyrrolopyrimidine hinge binding group and the central
pyridine substituent. Conversely, signiﬁcant metabolism is
observed at multiple sites of des-amino pyrrolopyrimidine 5,
the major sites being the pyrrolopyrimidine hinge binding
group and the central pyridine substituent. A very minor
product of amide hydrolysis was also observed. Incubation of
structurally similar analogue (R)-2-(4-cyanophenyl)-N-(4-(7-
(1-hydroxypropan-2-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-
carbonyl)pyridin-2-yl)acetamide (PF-05302191)55 in human
liver S9 (no additional NADP) showed formation of a mono-
oxidized metabolite (see Supporting Information, page S5). In
the presence of 50 μM menadione (an AO inhibitor), a
dramatic reduction in the formation of this metabolite was
observed, whereas preincubation with 50 μM allopurinol (XO
inhibitor) showed no change in metabolite proﬁle. These
observations would suggest that metabolism in human liver S9
fractions in this series is most likely due to AO.
Over the past few years, AO has been increasingly recognized
as playing an important role in drug metabolism, with reported
examples in which metabolism by this enzyme has had
signiﬁcant clinical impact or led to the termination of a drug
development program.56 In drug discovery, a method of
predicting CL parameters in humans with high conﬁdence is
highly desirable to make accurate dose predictions and, while
methods of scaling in vitro intrinsic CL data to predict the in
vivo metabolic CL of compounds are well-established for CYP
P450-dominated CL, similar methods have not yet been
established for drugs metabolized by AO. As a result, the
impact of having AO-mediated metabolism cannot be fully
established until the compound has reached the clinic.
Numerous medicinal chemistry design strategies aimed at
avoiding AO metabolism have been reported.57 As highlighted
in Figure 9, the AO-mediated oxidation of the des-amino
pyrrolopyrimidine group is more signiﬁcant than for the 4-
amino pyrolopyrimidine motif. However, as the des-amino
pyrrolopyrimidine confers an enhanced kinase selectivity
proﬁle, strategies to minimize AO oxidation on the more
kinase-selective des-amino pyrrolopyrimidine template were
investigated. The ﬁrst step in an AO-mediated oxidation
involves a nucleophilic attack on a heterocyclic ring system by
the molybdenum pyranopterin cofactor MoCo,58 hence an
initial strategy to minimize AO liability on the des-amino
pyrrolopyrimidine template was to increase the electron density
of that group by replacing the pyrimidine with a pyridyl motif.
Gratifyingly, the pyrimidyl to pyridyl transformation generated
compounds that maintained potent Trk activity, high kinase
selectivity, and were devoid of AO-mediated oxidation on the
pyridyl-containing hinge binding moiety. An example of from
the pyrrolopyridine series, 7,59 is highlighted in Table 2.
Compound 7 is a potent pan-Trk inhibitor, with an improved
lipophilic eﬃciency of LipE 4.9 due to a reduced log D relative
Figure 9. Sites of AO-mediated oxidation of des-amino pyrrolopyr-
imidines 5 and amino pyrrolopyrimidine 6.
Table 2. Structure and Properties of Compounds 5−7 (ND = Not Determined)
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to previous analogues. Compound 7 has low metabolic
turnover in HLM and hHep, is a good substrate for both the
eﬄux transporters P-gp (ER = 29) and BCRP (ER = 13), and
has moderate passive permeability (RRCK Papp = 11.3 × 10
−6
cms−1). The aqueous solubility of 7 is 7.5 μM. Compound 7
has an exquisitely selective kinase selectivity proﬁle, with a Gini
score of 0.96 (Figure 12). However, the introduction of the
weakly basic pyridyl atom (pKa 6.5) as part of the
pyrrolopyridyl ring engenders increased hERG activity (func-
tional hERG IC50 = 1.6 μM). Incubation of 7 in human S9 (no
added NADP) showed no evidence of AO-mediated oxidation
on the pyrrolopyridine hinge binding group and a low level of
metabolism of the central pyridine substituent (HPLC-UV
chromatograms are available in Supporting Information, page
S6). Interestingly, AO-mediated metabolism on the central
pyridyl ring is ablated if the N-atom is located at the 2- or 4-
position (Table 2), in these cases, however, compounds are
subject to chemical instability (if the nitrogen atom is located at
the 2- position) or signiﬁcant GSK3β kinase activity (if the
nitrogen atom is located at the 4- position). Hence, the 3-
pyridyl ring was established as the best isomer with which to
continue the lead optimization process.
The pharmacokinetic and brain penetration proﬁle of 7 was
assessed in vivo. Intravenous (iv) and oral (po) dosing in rats
was conducted at 1 and 3 mg/kg, respectively. Compound 7
has a high systemic CL (blood CL 50 mL/min/kg, ∼70%
hepatic blood ﬂow), moderate volume of distribution (Vss 1.5
L/kg), short half-life (2.3 h), and a relatively low bioavailability
(F% 16). The calculated fraction absorbed (0.55) was however
encouraging, suggesting that active transport may not
signiﬁcantly impede oral absorption in this series. To determine
the extent of peripheral restriction, 7 was administered orally at
100 mg/kg, with terminal plasma and brain samples taken 3 h
post dose. This study demonstrated a very low unbound brain/
plasma concentration ratio (Cb,u/Cp,u) of 0.0083. In addition,
Trk receptor occupancies in brain lysates were assessed using
the ActivX biotinylated acyl phosphate ADP probe. No
measurable TrkB or TrkC occupancy was detected.
The ability of 7 to reverse pain responses in vivo was assessed
in an ultraviolet (UV) irradiation induced hyperalgesia (UVIH)
model of inﬂammatory pain (see Supporting Information, page
S7). Analysis of the associated plasma exposure of 7 indicated
that statistically signiﬁcant eﬃcacy was observed at unbound
plasma concentrations of ≥1× TrkA IC50 with a maximal
eﬃcacy response at unbound plasma concentration of ∼10×
TrkA IC50. Compound 7 was well tolerated in a 7-day rodent
toxicology study up to the highest dose tested of 400 mg/kg/
day. Thus, we demonstrate that 7 is a potent and selective
inhibitor of Trk tyrosine kinases, is orally absorbed and highly
peripherally restricted, exhibits robust antinociceptive eﬀects in
the UVIH model of inﬂammatory pain, and is well tolerated in
vivo. While the hERG liability of 7 was not optimal, the
promising data generated on 7 enabled the project team to
enter candidate-seeking mode.
Candidate-Seeking. As outlined above, the AO-liability of
the pyrrolopyrimidine series can be mitigated by replacing the
pyrimidyl “head group” with a pyridyl motif, albeit with the
introduction of hERG activity. To attenuate the hERG liability
associated with the pyrrolopyridine series, the basicity of the
pyridyl group was modulated via the addition of a ﬂuorine atom
at the meta position. This pKa-lowering strategy delivered
compounds with comparable Trk potency (albeit with lower
Table 3. Structure and Property Comparison of Pyrimidine, Pyridine, Fluoro-pyrrolopyridine, and 2-Aminopyrimidine
Containing Trk Ligands (ND = Not Determined)
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LipE), metabolic stability and kinase selectivity, and with an
improved hERG liability proﬁle relative to pyrrolopyridine
analogues. Table 3 highlights example ﬂuoro-pyrrolopyridine
1059 and comparator pyrimidine and pyridine analogues 838
and 9.59 MetID analysis of the ﬂuoropyridyl ring of 2-(4-
chlorophenyl)-N-(2-(7-ﬂuoro-1-isopropyl-1H-pyrrolo[3,2-c]-
pyridine-3-carbonyl)pyridin-4-yl)acetamide (PF-06287755,59 a
structurally similar analogue of ﬂuoropyridyl 10) in human S9
in the absence of NADP conﬁrmed no AO oxidation at the
ﬂuoro-pyrrolopyridine motif (see Supporting Information, page
S8).
An alternative strategy to remove AO-liability is to add a
“blocking group” at the metabolically labile position. In the
pyrrolopyrimidine series, an −NH2 group was assessed as a
blocking group at the labile 2-position. This strategy delivered
compounds with comparable or improved potency, LipE, and
hERG proﬁles. MetID studies with human S9 in the absence of
NADP conﬁrmed no AO-mediated oxidation on the 2-
aminopyrimidyl ring. Table 1 highlights example 2-amino-
pyrimidine, compound 11.38
Interestingly, the kinase selectivity selective proﬁle of 2-
aminopyrrolopyrimidine 11 is comparable to des-amino
pyrrolopyrimidine 8 (Table 2) even though there is the
potential for an additional H-bond with the conserved hinge
region. However, as exempliﬁed in Figure 10, the −NH2 group
of the 2-aminopyrrolopyrimidine hinge binder makes an
imperfect hydrogen bonding interaction with the backbone
carbonyl of hinge residue Met592. Because of the suboptimal
geometry of the donor−acceptor−donor arrangement (O···H−
N bond angle is 123°, cf., an ideal O···H−N bond angle of
180°) the additional hydrogen bond may not signiﬁcantly
contribute to the free energy of binding and hence not erode
kinase selectivity.60
Overall, the 2-aminopyrrolopyrimidine headgroup conferred
the best balance of properties of the hinge binding groups
assessed although the aqueous solubility was still relatively low.
Compound 12,38 an exemplar 2-aminopyrrolopyrimidine
(Table 4), is a potent and selective Trk kinase inhibitor with
a high P-gp ER and minimal hERG liability. As with other 2-
aminopyrrolopyrimidines, there is no AO oxidation on the
aminopyrrolopyrimidine ring. The log D is high (4.2), likely
contributing to the relatively poor solubility of 12 μM. To
design 2-aminopyrrolopyrimidine analogues with enhanced
solubility and an improved LipE proﬁle, compounds of reduced
log D were required. An analysis of available Trk cocrystal
structures suggested polar groups would be tolerated at the
N-iPr motif of 2-aminopyrrolopyrimidine compounds such as
12, as this region of the binding site is highly solvent accessible.
Addition of a solubilizing hydroxymethylene group to N-iPr
motif generated compounds such as 1338 that retained Trk
potency, increased LipE due to a lower log D, and eﬀected an
improved solubility proﬁle. In addition, replacement of the
chlorophenyl ring of with a lower log D pyridyl motif delivered
ligands such as 14 which had further optimized LipE and
solubility proﬁles.
As highlighted in Table 4, 14 is a highly potent pan-Trk
inhibitor, with an excellent LipE proﬁle. Compound 14 has low
metabolic turnover in HLM and hHep is a good substrate for
eﬄux transporters P-gp (ER = 35.7) and BCRP (ER = 4.0) and
has moderate passive permeability (RRCK Papp = 5.4 × 10
−6 cm
s−1). Its oxidation by AO on the amino pyrrolopyrimidine
substituent in human S9 is minimal (see Supporting
Information, page S9), and only a low level of metabolism by
AO is detected on the central pyridyl ring. The aqueous
solubility of 14 is 131 μM, much improved over previous
analogues, it is highly kinase-selective (Gini score of 0.92) and
has no measurable activity at the hERG channel. Compound 14
was proﬁled in a series of in vitro safety assays, showing little
cytotoxicity in THLE or HepG2 cell lines (IC50 > 42 μM and
>300 μM, respectively) and was evaluated for broader
pharmacological activity in a panel of receptors, ion channels,
and enzymes. In this broad panel, all IC50/Ki values were >10
μM except for COX-1 (IC50 = 2.7 μM) and dopamine
transporter assays (Ki = 5.2 μM) and PDEs 4D, 5A, 7B, 8B, and
11 (54−89% inhibition at 10 μM). Compound 14 was screened
in the Invitrogen wide kinase panel of 309 kinases, and all were
inhibited by <40% when tested at 1 μM except the following:
MUSK (IC50 53 nM), FLT-3 (IC50 395 nM), IRAK1 (IC50 2.5
μM), MKK (90% @ 1 μM), and DDR1 (60% @ 1 μM).
Figure 11 shows the crystal structure of 14 bound to TrkA
kinase and highlights key protein−ligand interactions. Com-
pound 14 adopts a DFG-out binding mode, with the 2-amino
pyrrolopyrimidine hinge binding motif making a hydrogen
bonding interaction to the backbone N−H of Met592 via a
pyrimidyl nitrogen and with a “through water” hydrogen bond
network between main chain carbonyl Glu590 and the ketone
oxygen atom of 14. An additional hydrogen bond exists
between the −NH2 group of the 2-aminopyrrolopyrimidine
hinge binder and the backbone carbonyl of hinge residue A592
but with suboptimal geometry (O···H−N bond angle, 122°).
The central pyridyl group of 14 makes a π-stacking interaction
with the gatekeeper (Phe589) and Phe669 of the DFG triad.
The carbonyl oxygen of the amide group makes a hydrogen
bond interaction with the backbone N−H of Asp 668 from the
DFG triad, and the amide N−H group makes a hydrogen bond
to a conserved water molecule which further interacts with
catalytic lysine (Lys544) and Glu560 from the α-C helix. The
lipophilic back pocket accommodates the chloropyridyl group.
Brain availability experiments with 14 in rat conﬁrmed
signiﬁcant peripheral restriction, with Cb,u/Cp,u = 0.026. In
addition, no measurable TrkB or TrkC occupancy was detected
from brain lysates using the ActivX biotinylated acyl phosphate
Figure 10. Hydrogen bond interactions of 2-aminopyrrolopyrimidine
group with the TrkA hinge binding region (blue). The red circle
highlights the nonoptimal bond angle between backbone carbonyl
A592 and the ligand−NH2.
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ADP probe. Compound 14 was assessed in the UVIH model of
inﬂammatory pain in rodents. In this study, statistically
signiﬁcant eﬃcacy was observed at unbound plasma concen-
trations of ≥1× TrkA IC50, with maximal eﬃcacy response at
an unbound plasma concentrations of ∼10× TrkA IC50 (see
Supporting Information, page S10). The safety proﬁle of 14
was assessed in vivo. In rats, decreases in white blood cell count
were observed from 150 mg/kg/day. At doses ≥250 mg/kg,
increases in body weight gain and food consumption were
observed, eﬀects that could be rationalized as being mediated
by central inhibition of TrkB, agonists of which are known to
be anorexigenic in rodents. Adaptive changes in the liver were
observed microscopically and accompanied by increased liver
weight at ≥250 mg/kg and increased cholesterol at 1000 mg/
kg. Overall, 14 was well tolerated up to 1000 mg/kg/day where
plasma exposure (unbound Cavg) was approximately 400×
TrkA IC50.
In summary, 14 is a highly potent, kinase-selective,
peripherally restricted, eﬃcacious, and well-tolerated pan-Trk
inhibitor and was selected as a candidate for clinical
development.
Compound Synthesis. The synthetic route toward 14 is
described in Scheme 1.38 Iodination of 15 with NIS gave
monoiodinated 16 in good yield. Compound 16 was
subsequently alkylated with methyl 2-bromo-2-methylpropa-
noate using cesium carbonate as base to aﬀord 17. Ester
hydrolysis of 17 generated 18 in good yield, which was then
reduced to give 19. The reduction step to aﬀord 19 proved
challenging, and a range of conditions were examined with
DIBAL-H and superhydride proving most eﬀective. DIBAL-H
was utilized as the reducing agent upon scale-up. A subsequent
Table 4. Trk Pharmacology and in Vitro ADME Proﬁles of 2-Aminopyrimidine Compounds 12, 13, and 14
Figure 11. Crystal structure of 14 (green) bound to TrkA (pink). The hinge region of the TrkA ATP site is highlighted in blue. The “DFG” triad of
the activation loop of TrkA is highlighted in orange. Key protein−ligand binding interactions are outlined.
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protection of the resulting primary alcohol with t-butyldime-
thylsilyl chloride and imidazole in DMF (0 °C to rt, 16 h)
delivered 20, the iodide coupling partner required for the
subsequent Weinreb ketone formation, in 96% yield. The
additional coupling partner for the ketone formation step,
Weinreb amide 22, was synthesized via the palladium mediated
cross-coupling of 21 and benzophenone imine. To elicit the
Weinreb ketone formation, isopropyl magnesium chloride was
added to 20 in THF at 0 °C. After stirring at 0 °C for 1 h, a
solution of Weinreb amide 22 in THF was added and the
resulting mixture stirred at rt for 16 h. Following ammonium
chloride quench and puriﬁcation via column chromatography,
23 was delivered in 66% yield. Chloro displacement of 23 with
2,4-dimethoxybenzylamine in DMAP and 1,4-dioxane, followed
by deprotection of the benzophenoneimine group with citric
acid in THF, aﬀorded 24 in 78% yield. Amidation of 24 was
achieved via treatment with (5-chloropyridin-2-yl)acetic acid, 1-
propylphosphonic acid cyclic anhydride (T3P), and triethyl-
amine in THF. After workup and in vacuo concentration of the
organic extracts, the resultant crude oil was treated with
triﬂuoroacetic acid and stirred at 50 °C for 3 h. After this time,
the solution was concentrated, methanol and potassium
carbonate were added, and the resulting mixture was stirred
at rt for 16 h. The mixture was poured into water, and the
resultant solid was ﬁltered and triturated with EtOH to aﬀord
14 in 48% yield.
■ CONCLUSION
The tropomyosin related kinase (Trk) family of tyrosine kinase
receptors represents an important target class in the pain
therapy ﬁeld. In addition to delivering the requisite analgesic
eﬀects, a key requirement is to deliver a therapeutic agent with
a very benign safety side eﬀect proﬁle. Kinases modulate
numerous physiological functions,26,27 so designing highly
kinome-selective Trk kinase inhibitors is a key objective.
Within the Pﬁzer Trk project, chemical series with an
anticipated DFG-out binding mode were prioritized for
follow-up, as kinase inhibitors that bind to less conserved
areas of the ligand binding domain, outside of the ATP binding
pocket, can sometimes be more kinase-selective.32,33,35,36,40 An
additional requirement is to deliver Trk ligands with minimal
brain availability at therapeutically relevant doses due to the
known safety (cognitive) side eﬀects associated with inhibiting
Trk receptors in the CNS. The strategy employed to deliver
peripherally restricted, orally bioavailable compounds was to
design compounds in physicochemical space appropriate for
absorption across the gastrointestinal epithelium that act as
substrates for blood−brain barrier eﬄux transporters such as P-
glycoprotein (P-gp).22
A high throughput screening campaign identiﬁed a “DFG-
out” pyrrolopyrimidine series: potent pan-Trk inhibitors with
moderate LipE, encouraging kinase selectivity and P-gp aﬃnity,
but very poorly soluble. Following a matched molecular pair
analysis, the urea motif was replaced with an amide group to
improve solubility while maintaining Trk activity. The extent of
in vitro P-gp activity required to deliver signiﬁcant peripheral
restriction in vivo was established by assessing the Cb,u/Cp,u and
brain Trk RO (using a chemical proteomic technology
developed by ActivX Biosciences Inc.) of compounds with P-
gp ER in the range 1−50. These data, alongside an analysis of
the performance of an in-house 2D QSAR P-gp ER model,
were utilized to guide the prospective design of compounds
with a high in vitro P-gp ER and hence signiﬁcant peripheral
restriction in vivo. Optimization of kinase selectivity was
achieved by reducing the extent of polar contact made between
the ligand and the backbone polar atoms of the conserved
kinase hinge residues via analysis of the apo versus holo crystal
structures and replacing a protein−ligand hydrogen bond with
a relatively rare “bridging” water molecule. Further optimization
of the hinge binding group to minimize AO liability and the use
of SBDD to add additional polar group functionality to
modulate log D delivered highly potent, kinase-selective,
peripherally restricted, eﬃcacious, and well-tolerated pan-Trk
inhibitors. Compound 14 was selected as a candidate for
clinical development and clinical data will be published in due
course.
Figure 12. Heat map representation of the Invitrogen selectivity panel data of 39 kinases for 1, 3, 4, 7, and 14, %I values generated at a compound
concentration of 1 μM. 0%I = green, 50%I = yellow, 100%I = red.
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■ EXPERIMENTAL SECTION
Starting materials and other reagents were purchased from commercial
suppliers and were used without further puriﬁcation unless otherwise
indicated. All reactions were performed under a positive pressure of
nitrogen, argon, or with a drying tube at ambient temperature (unless
otherwise stated) in anhydrous solvents, unless otherwise indicated.
Analytical thin-layer chromatography was performed on glass-backed
silica gel 60_F 254 plates (Analtech (0.25 mm)) and eluted with the
appropriate solvent ratios (v/v). The reactions were assayed by high
performance liquid chromatography (HPLC) or thin-layer chromatog-
raphy (TLC) and terminated as judged by the consumption of starting
material. The TLC plates were visualized by phosphomolybdic acid
stain or iodine stain. Microwave assisted reactions were run in a
Biotage initiator. 1H NMR spectra were recorded on a Bruker
instrument operating at 400 MHz unless otherwise indicated. 1H
NMR spectra were obtained as DMSO-d6 or CDCl3 solutions as
indicated (reported in ppm), using chloroform as the reference
standard (7.25 ppm) or DMSO-d6 (2.50 ppm). Other NMR solvents
were used as needed. When peak multiplicities are reported, the
following abbreviations are used: s = singlet, d = doublet, t = triplet, m
= multiplet, br = broadened, dd = doublet of doublets, dt = doublet of
triplets. Coupling constants, when given, are reported in hertz. Mass
spectral data were obtained using Waters ZQ ESCI or Applied
Biosystem’s API-2000. Chemical purities were >95% for all ﬁnal
compounds as assessed by LCMS, with UV detection at 220 and/or
254 nm. Further details on the analytical conditions used for individual
compounds may be found in the Supporting Information. The
chemical yields reported below are unoptimized speciﬁc examples of
one preparation. The chemical yields reported are unoptimized
speciﬁc examples of one preparation. Compound 14 is commercially
available via Sigma-Aldrich (catalogue no. PZ0254).
N-(5-{[2-Amino-7-(2-hydroxy-1,1-dimethylethyl)-7H-pyrrolo-
[2,3-d]pyrimidin-5-yl]carbonyl}pyridin-3-yl)-2-(5-chloropyri-
din-2-yl)acetamide (14). (5-Chloropyridin-2-yl)acetic acid (26.1 g,
152 mmol) was added to 24 (75.0 g, 130 mmol), 1-propylphosphonic
acid cyclic anhydride (187 mL, 317 mmol, 50% solution in EtOAc),
and triethylamine (61.9 mL, 444 mmol) in THF (423 mL). The
mixture was stirred at 25 °C for 2 h, and then saturated aqueous
sodium bicarbonate (400 mL) was added and the organic layer was
separated. The aqueous phase was extracted with EtOAc (400 mL),
and all organic phases were combined and dried over sodium sulfate
and then evaporated in vacuo. The residual brown solid was dissolved
in triﬂuoroacetic acid (300 mL), and the solution was stirred at 50 °C
for 3 h and then evaporated in vacuo. Methanol (1800 mL) was added
to the residue, and the mixture was ﬁltered. The ﬁltrate was evaporated
in vacuo and azeotroped with ethanol (3 × 200 mL). Potassium
carbonate (87.7 g, mmol) was added to the crude triﬂuoroacetamide in
methanol (300 mL), and the mixture was stirred at room temperature
for 16 h. The mixture was poured into water (2000 mL) and ﬁltered.
Scheme 1. Synthesis of 14a
aReagents and conditions: (i) NIS, MeCN, 12 °C to rt, 1 h, 82%; (ii) BrMe2CO2Me, KI, Cs2CO3, DMF, 60°C, 19 h, 92%; (iii) LiOH, THF/H2O,
60 °C, 3 h, 90%; (iv) DIBAL-H, THF, 0 °C, 1.5 h, 56%; (v) TBMS-Cl, imidazole, DMF, 0 °C to rt, 16 h, 96%; (vi) benzophenone imine, Pd2(dba)3,
K3PO4, DME, 50 °C, 17 h, 51%; (vii) 20, i-PrMgCl, THF, 0 °C, then 22, THF, 0 °C to rt, 16 h, 66%; (viii) 2,4-dimethoxybenzylamine, DMAP, 1,4-
dioxane, reﬂux, 2 d, then citric acid, THF, rt, 5 h, 78%; (viiii) 2-(5-chloropyridin-2-yl)acetic acid, T3P, Et3N, THF, rt, 2 h, then TFA, 50°C, 3 h, then
K2CO3, MeOH, rt, 16 h, 48%.
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The solid was washed with water (200 mL) and then triturated with
ethanol (2 × 200 mL at room temperature then 380 mL at 50 °C) to
aﬀord the title compound as a yellow solid in 48% yield, 29.9 g. 1H
NMR (400 MHz, DMSO-d6) δ: 1.64 (s, 6H), 3.90 (d, J = 5.5, 2H),
3.95 (s, 2H), 5.05 (dd, J = 5.7, 5.5, 1H), 6.54 (br s, 2H), 7.49 (d, J =
8.4, 1H), 7.69 (s, 1H), 7.92 (dd, J = 8.3, 2.4, 1H), 8.40 (m, 1H), 8.56
(d, J = 2.5, 1H), 8.64 (d, J = 1.8, 1H), 8.94 (d, J = 2.2, 1H), 8.96 (s,
1H), 10.71 (s, 1H). HPLC (6 min, acid) Rt 1.26 min; UV 220 nM
100% purity; LC-MS (ES−) m/z 478 (M − H+); HRMS (ES+) m/z
480.15468 (M + H+).
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derived neurotrophic factor; BBB, blood−brain barrier; Cb,u/
Cp,u, unbound brain/plasma concentration ratio; Cavg, average
plasma concentration; CL, clearance; CLint, intrinsic clearance;
CNS, central nervous system; CSDb, Pﬁzer Crystal Structure
Database; CYP, cytochrome P450; DDI, drug−drug inter-
action; DIBAL-H, diisobutylaluminum hydride; Dof, dofetilide;
ER, eﬄux ratio; F, bioavailability; f u, fraction unbound; hERG,
human ether-a-go-go related gene; hHep, human hepatocytes;
HLM, human liver microsomes; IC50, half-maximum inhibitory
concentration; Ki, dissociation constant; Km, Michaelis−
Menten constant; LBF, liver blood ﬂow; LipE, lipophilic
eﬃciency; log D, distribution coeﬃcient at pH = 7.4; mAb,
monoclonal antibody; MDCK, Madine−Darby canine kidney;
MDR1, multidrug resistance protein (p-glycoprotein); MetID,
in vitro metabolite identiﬁcation; MMP, matched molecular
pair; NADP, nicotinamide adenine dinucleotide phosphate;
ND, not determined; NT3, neurotrophin 3; NT4, neurotrophin
4; NIS, N-iodosuccinimide; NGF, nerve growth factor; Papp,
apparent permeability; PDB, Protein Data Bank; P-gp, p-
glycoprotein; PK, pharmacokinetics; QSAR, quantitative
structure−activity relationship; RMSD, root-mean-square devi-
ation; RO, receptor occupancy; RRCK, Ralph Russ canine
kidney cell line, permeability measured with low-eﬄux MDCK
cell; SBDD, structure based drug design; T1/2, half-life; THLE,
transformed human liver epithelial cells; Trk, tropomyosin
related kinase; UVIH, ultraviolet burn induced hyperalgesia;
Vss, volume of distribution at steady state
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